Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899399 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LY96SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL18570428 | 0.87 | LY96 (0.40) | ALDH1A1LY96SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL903041 | 0.85 | ALDH1A1 (0.35) | ALDH1A1LY96SMN1; SMN2PYGL | |
| SCHEMBL902994 | 0.85 | ALDH1A1 (0.34) | ALDH1A1LY96SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL898778 | 0.79 | MTNR1A (0.35) | ALDH1A1MTNR1AMTNR1BLMNA | |
| SCHEMBL15294862 | 0.74 | LY96 (0.33) | ALDH1A1LY96SMN1; SMN2LMNAPYGL | |
| SCHEMBL15294864 | 0.72 | CA12 (0.33) | ALDH1A1LY96SMN1; SMN2LMNA | |
| SCHEMBL902926 | 0.71 | ALDH1A1 (0.33) | ALDH1A1LY96SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL21203114 | 0.69 | LY96 (0.39) | ALDH1A1LY96SMN1; SMN2CTSLCTSS | |
| SCHEMBL21203113 | 0.68 | LY96 (0.37) | ALDH1A1LY96SMN1; SMN2LMNACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2621903-A1 | N-HETEROARYL COMPOUNDS | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | ALDH1A1 1345/4885LY96 2451/4885SMN1; SMN2 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.